
Core patent protection for Matrix-M Adjuvant extends through 2044 and beyond. Predicting Novavax will be ACQUIRED due to the $BILLIONS in revenues Matrix-M will bring to the buyer over the next few decades with adjuvanted Cancer, Infectious Disease, C.Diff., and Respiratory Vaccines. $NVAX #Biotech $IBB $XBI https://t.co/JollrXJ5vH
